LRRK2 (R1441C)

LRRK2 · Variant type: point · HGVS: p.R1441C

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Brigatinib	99.2%	0.8%	82.96
2	Ceritinib	97.3%	2.7%	95.44
3	Alectinib	96.1%	3.9%	95.49
4	Axitinib	91.1%	8.9%	93.23
5	Ponatinib	88.6%	11.4%	78.23
6	Sunitinib	85.2%	14.8%	91.73
7	Osimertinib	77.2%	22.8%	97.24
8	Bosutinib	74.6%	25.4%	87.22
9	Nintedanib	69.9%	30.1%	90.23
10	Ruxolitinib	62.2%	37.8%	98.25
11	Gilteritinib	60.8%	39.2%	88.97
12	Fostamatinib	57.8%	42.2%	96.74
13	Defactinib	57.3%	42.7%	92.68
14	Lenvatinib	52.6%	47.4%	97.74
15	Baricitinib	50.6%	49.4%	97.99
16	Lorlatinib	50.4%	49.6%	97.24
17	Vemurafenib	49.6%	50.4%	96.49
18	Rabusertib	49.4%	50.6%	98.74
19	Pacritinib	42.1%	57.9%	88.64
20	Paxalisib	36.7%	63.3%	99.75
21	Selpercatinib	36.0%	64.0%	96.72
22	Abemaciclib	35.9%	64.1%	91.48
23	Repotrectinib	31.8%	68.2%	84.21
24	Fedratinib	28.1%	71.9%	96.21
25	Abrocitinib	24.7%	75.3%	99.50

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Brigatinib	99.2%	96.6%	+2.6%
Ceritinib	97.3%	99.4%	-2.2%
Alectinib	96.1%	94.5%	+1.5%
Axitinib	91.1%	92.3%	-1.2%
Ponatinib	88.6%	63.4%	+25.2%
Sunitinib	85.2%	95.8%	-10.6%
Osimertinib	77.2%	82.4%	-5.2%
Bosutinib	74.6%	69.5%	+5.0%
Nintedanib	69.9%	67.2%	+2.8%
Ruxolitinib	62.2%	63.0%	-0.8%
Gilteritinib	60.8%	97.2%	-36.4%
Fostamatinib	57.8%	69.3%	-11.5%
Defactinib	57.3%	95.8%	-38.5%
Lenvatinib	52.6%	—	—
Baricitinib	50.6%	62.8%	-12.1%
Lorlatinib	50.4%	—	—
Vemurafenib	49.6%	—	—
Rabusertib	49.4%	—	—
Pacritinib	42.1%	83.4%	-41.3%
Paxalisib	36.7%	—	—
Selpercatinib	36.0%	—	—
Abemaciclib	35.9%	79.1%	-43.2%
Repotrectinib	31.8%	68.8%	-37.0%
Fedratinib	28.1%	—	—
Abrocitinib	24.7%	62.1%	-37.5%

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.5ms